IMMUTEP LIMITED - AMER

Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

03 6 2022 13:18:08 提供 Nasdaq GlobeNewswire

Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022

02 6 2022 07:00:03 提供 Nasdaq GlobeNewswire

Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022

27 5 2022 07:00:00 提供 Nasdaq GlobeNewswire

Immutep to Present at Investor Conferences

20 5 2022 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Appoints Leading Oncologists to its Clinical Advisory Board

18 5 2022 07:00:01 提供 Nasdaq GlobeNewswire

Immutep Presents New and Significant Data from the AIPAC Study

04 5 2022 07:00:02 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

29 4 2022 07:00:00 提供 Nasdaq GlobeNewswire

Immutep to Announce New TACTI-002 Data in an Oral Presentation at the ASCO 2022 Annual Meeting

28 4 2022 07:00:02 提供 Nasdaq GlobeNewswire

Immutep’s Efti in Combination with MSD’s Pembrolizumab Shows Encouraging Antitumor Activity in Difficult to Treat 2nd Line Metastatic Lung Cancer Patients

30 3 2022 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Announces Publication of TACTI-002 Abstract at ESMO’s European Lung Cancer Congress 2022

24 3 2022 07:00:01 提供 Nasdaq GlobeNewswire

Immutep Announces Second Japanese Patent Grant for LAG-3 Antagonist Antibody LAG525

18 3 2022 07:00:00 提供 Nasdaq GlobeNewswire

Immutep To Present Biomarker And Multivariate Analysis From Phase IIb AIPAC Study In Metastatic Breast Cancer At ESMO’s Breast Cancer Congress 2022

18 3 2022 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Receives Constructive Feedback from US FDA on its Clinical Development Program for EFTI in Metastatic Breast Cancer

10 3 2022 07:00:02 提供 Nasdaq GlobeNewswire

Immutep to Present at Healthcare Investor Conferences

24 2 2022 07:00:01 提供 Nasdaq GlobeNewswire

Immutep to Present New Data from the Phase II TACTI-002 Study of Efti at ESMO’s European Lung Cancer Congress 2022

18 2 2022 07:00:00 提供 Nasdaq GlobeNewswire

Immutep Granted Australian Patent for Eftilagimod Alpha, a Soluble LAG-3 Protein, in Combination with a PD-1 Pathway Inhibitor

11 2 2022 07:00:00 提供 Nasdaq GlobeNewswire

Immutep to Present at February Investor Conferences

31 1 2022 07:00:02 提供 Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

25 1 2022 07:00:01 提供 Nasdaq GlobeNewswire

Immutep Advances IMP761 Manufacturing

16 12 2021 07:00:02 提供 Nasdaq GlobeNewswire

Immutep Reports Good Safety from First Five Patients in Triple Combination Therapy Efti Study, Insight-003

02 12 2021 07:00:01 提供 Nasdaq GlobeNewswire